Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.68 |
| ▸ | MTOR | P42345 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.68 |
| ▸ | MLNR | O43193 | 1/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.68 |
| ▸ | CNR1 | P21554 | 1/20 | 0.68 |
| ▸ | HRH1 | P35367 | 1/20 | 0.68 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.68 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.68 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.55 |
| ▸ | CACNA1C | Q13936 | 8/20 | 0.54 |
| ▸ | CACNA1F | O60840 | 7/20 | 0.54 |
| ▸ | CACNA1D | Q01668 | 7/20 | 0.54 |
| ▸ | CACNA1S | Q13698 | 7/20 | 0.54 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1434764 | 0.90 | ADORA3 (0.71) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| SCHEMBL1434762 | 0.88 | ADORA3 (0.68) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| SCHEMBL1434767 | 0.88 | ADORA3 (0.68) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| SCHEMBL5275957 | 0.82 | ADORA3 (0.90) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| SCHEMBL7590320 | 0.82 | ADORA3 (0.90) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| SCHEMBL8237206 | 0.82 | ADORA3 (0.83) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL25268 | 0.81 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL9957683 | 0.81 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL8415026 | 0.81 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 | |
| Lercanidipine SCHEMBL25269 | 0.81 | ADORA3 (1.00) | ADORA3ADRA1AMTORRAB9ASLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097729-B2 | Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof | GLENMARK GENERICS LTD. (IN) | 2012-01-17 | — | — | US | claimed |
| US-20090221833-A1 | Polymorphic Form of Lercanidipine Hydrochloride and Process for the Preparation Thereof | ALIVUS LIFE SCIENCES LIMITED (IN) | 2009-09-03 | — | — | US | claimed |
| EP-1940790-A2 | POLYMORPHIC FORM OF LERCANIDIPINE HYDROCHLORIDE AND PROCESS FOR THE PREPARATION THEREOF | Glenmark Pharmaceuticals Limited (IN) | 2008-07-09 | — | — | EP | claimed |
| WO-2007031865-A2 | POLYMORPHIC FORM OF LERCANIDIPINE HYDROCHLORIDE AND PROCESS FOR THE PREPARATION THEREOF | GLENMARK PHARMACEUTICALS LIMITED (US) | 2007-03-22 | — | — | WO | claimed |
| EP-1940790-B1 | POLYMORPHIC FORM OF LERCANIDIPINE HYDROCHLORIDE AND PROCESS FOR THE PREPARATION THEREOF | GLENMARK PHARMACEUTICALS LTD (IN) | 2015-09-02 | — | — | EP | disclosed |
| US-8097729-B2 | Polymorphic form of lercanidipine hydrochloride and process for the preparation thereof | GLENMARK GENERICS LTD. (IN) | 2012-01-17 | — | — | US | disclosed |
| US-20090221833-A1 | Polymorphic Form of Lercanidipine Hydrochloride and Process for the Preparation Thereof | ALIVUS LIFE SCIENCES LIMITED (IN) | 2009-09-03 | — | — | US | disclosed |
| EP-1940790-A2 | POLYMORPHIC FORM OF LERCANIDIPINE HYDROCHLORIDE AND PROCESS FOR THE PREPARATION THEREOF | Glenmark Pharmaceuticals Limited (IN) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007031865-A2 | POLYMORPHIC FORM OF LERCANIDIPINE HYDROCHLORIDE AND PROCESS FOR THE PREPARATION THEREOF | GLENMARK PHARMACEUTICALS LIMITED (US) | 2007-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221833-A1 | Polymorphic Form of Lercanidipine Hydrochloride and Process for the Preparation Thereof | ADH1C, ADH5, CYP3A4 | ADORA3 1998/4885ADRA1A 49/4885MTOR 4168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.